<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1157">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04351516</url>
  </required_header>
  <id_info>
    <org_study_id>COVID65plus</org_study_id>
    <secondary_id>2020-001482-37</secondary_id>
    <nct_id>NCT04351516</nct_id>
  </id_info>
  <brief_title>Test and Treat COVID 65plus+</brief_title>
  <acronym>COVID65plus</acronym>
  <official_title>Randomized Controlled Trial of Hydroxychloroquine Versus Placebo in Early Ambulatory Diagnosis and Treatment of Elderly COVID19 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients over equal or older than 65 yearswill be treated with a hydroxychloroquine versus
      placebo reduced loading dose of 600mg on the first day followed with 400mg/day divided in
      2x200mg for 6 more days resulting in a total duration of therapy of 7 days. Measurement of
      Hydroxychloroquine-levels will be performed on day 7, . A follow-up by video or telephone
      conference will be performed to observe drug intake and collect adverse events during
      treatment phase on a daily base on working days and once during the weekend (i.e. 6 out of 7
      days). After treatment phase follow-up by telephone calls will be done on day 10, 30, 60 (+/-
      2 days).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 21, 2020</start_date>
  <completion_date type="Anticipated">May 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>● Rate of hospitalization or death at day 7 after study inclusion</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>SARS-CoV 2</condition>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>hydroxychloroquine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>dose of 600mg on the first day followed with 400mg/day divided in 2x200mg for 6 more days</description>
    <arm_group_label>hydroxychloroquine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo: Film Coated Tablette</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Age ≥ 65 years

          -  Mild to moderate symptomatic respiratory tract Infection defined as not requiring
             hospital admission: SpO2 &gt;94%, respiratory rate &lt;20, mental state alert, no signs of
             septic shock

          -  Proven SARS-Cov2 infection by throat swab (PCR)

          -  Onset of symptoms within the last 3 days before randomization

          -  Must be able to adhere to the study visit schedule and other protocol requirements in
             the investigator's opinion. I.e. must be able to answer to questions concerning
             symptoms and side effects and must be able to consent to the informed consent.

        Exclusion Criteria:

          -  Hospitalization at study inclusion

          -  Weight &lt;50 kg

          -  Acute myocardial infarction

          -  Severe heart failure, characterized as NYHA class 3 or 4

          -  Use of concomitant medications that prolong the QT/QTc interval.

          -  QTc &gt;450ms

          -  Bilirubin ≥ 1,5 x UNL, (except for known M. Meulengracht)

          -  AST/ALT ≥ 3 x ULN

          -  Albumine ≤ 2.8 g/dl

          -  Hemoglobin ≤ 9 g/dl

          -  Leucocytes ≤ 2000/µl

          -  Neutrophiles ≤ 1000/µl

          -  Thrombocytes ≤ 100.000/µl

          -  Troponin elevation

          -  BNP &gt; 500 pg/ml

          -  Creatine kinase &gt; 5 x ULN

          -  Creatinine &gt;1,5 mg/dl

          -  Uncorrected hypopotassemia or hypomagnesemia

          -  History of hypoglycemic events

          -  History of or present cardial arrhythmia (except atrial fibrillation or paroxysmal
             supraventricular tachycardia)

          -  Bradycardia &lt; 60 beats/min

          -  History of Retinopathy or Maculopathy

          -  Psoriasis

          -  Myasthenia gravis

          -  Epilepsy

          -  Immunodeficiency syndromes or need for highly immunosuppressive medication

          -  Pre-existing medication with hydroxychloroquine

          -  Known G6PD deficiency.

          -  Participation in another interventional study

          -  Known hypersensibility to hydroxychloroquine and its derivates
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michael Bitzer, MD</last_name>
    <phone>+49 7071 2985629</phone>
    <email>michael.bitzer@med.uni-tuebingen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Manola Zago, PhD</last_name>
    <email>zks-pm@med.uni-tuebingen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Uniklinikum Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Bitzer, MD</last_name>
      <email>michael.bitzer@med.uni-tuebingen.de</email>
    </contact>
    <investigator>
      <last_name>Siri Göpel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Seufferlein, MD</last_name>
      <phone>+49 731 50044501</phone>
      <email>thomas.seufferlein@uniklinik-ulm.de</email>
    </contact>
    <investigator>
      <last_name>Lukas Perkhofer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 15, 2020</study_first_submitted>
  <study_first_submitted_qc>April 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2020</study_first_posted>
  <last_update_submitted>May 26, 2020</last_update_submitted>
  <last_update_submitted_qc>May 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

